Antibody fragments in therapy

Details Antibody fragments in therapy Antibody fragments in therapy

C - Chemistry, Metallurgy

07

K

C07K 16/24 (2006.01) A61K 39/395 (2006.01) C07K 16/06 (2006.01) C07K 16/44 (2006.01) C12N 9/50 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2163032

A method of neutralising TNF.alpha. in a patient benifiting from such neutralising, comprising administering to the patient IgG Fab fragment reactive towards TNF.alpha.. Suitably, the patient is suffering from septic shock or from the symptoms of septic shock. It is preferred if the Fab fragment is derived from polyclonal IgG.

L'invention concerne un procédé de neutralisation du facteur de nécrose tumorale alpha (TNFalpha) appliqué à un patient et consistant à administrer au patient un fragment d'IgG Fab réagissant au TNFalpha; en particulier, le patient souffre du choc septique ou présente des symptômes du choc septique. Il est préférable que le fragment de Fab soit dérivé de l'IgG polyclonale.

Affiliated with

Also associated with

Rating

Antibody fragments in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody fragments in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fragments in therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1374319